Acute Exercise and Pancreatic Endocrine Function

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Thomas Solomon, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01812590
First received: March 14, 2013
Last updated: January 30, 2014
Last verified: January 2014

March 14, 2013
January 30, 2014
January 2013
June 2013   (final data collection date for primary outcome measure)
Pancreatic endocrine function [ Time Frame: 24-hours following a period of rest/exercise ] [ Designated as safety issue: No ]
Insulin and glucagon secretory responses to intravenous glucose (hyperglycemic clamp 5.4 mmol/l above basal), glucagon-like peptide-1 (0.5 pmol/kg/min), and arginine (5 g injection) will be determined.
Same as current
Complete list of historical versions of study NCT01812590 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Acute Exercise and Pancreatic Endocrine Function
Not Provided

Subjects with type 2 diabetes will be stratified into two-quantiles based on ambient hyperglycemia (fasting glucose and HbA1c) and then the effects of a single aerobic exercise bout (1-hour at 50%VO2max) on pancreatic endocrine function will be determined.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Type 2 Diabetes
Behavioral: Exercise
  • No Intervention: Resting Trial
    Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
  • Experimental: Exercise Trial
    Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
    Intervention: Behavioral: Exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
October 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previous diagnosis with type 2 diabetes, or newly detected in our screening procedures
  • Age 30-70 years
  • BMI 20-40 kg/m2

Exclusion Criteria:

  • Treatment with insulin
  • Contraindication to exercise as determined by ECG
  • Pregnancy
  • Active weight loss in the previous 6 months
  • Actively engaged in exercise training programs
  • Evidence of chronic pulmonary, cardiovascular, hepatic, renal, or hematological disease
Both
30 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01812590
Ex-Panc
Not Provided
Thomas Solomon, Rigshospitalet, Denmark
Rigshospitalet, Denmark
Not Provided
Not Provided
Rigshospitalet, Denmark
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP